Holen Sie sich die Stockscreener-App
13.99
2.71%
-0.39
Handel nachbörslich:
13.99
Schlusskurs vom Vortag:
$14.38
Offen:
$14.5
24-Stunden-Volumen:
746.64K
Relative Volume:
0.53
Marktkapitalisierung:
$1.54B
Einnahmen:
$-665.00K
Nettoeinkommen (Verlust:
$-144.74M
KGV:
-9.0101
EPS:
-1.5527
Netto-Cashflow:
$-123.48M
1W Leistung:
+1.01%
1M Leistung:
-0.92%
6M Leistung:
+20.09%
1J Leistung:
+281.20%
1-Tages-Spanne:
$13.78
$15.01
1-Wochen-Bereich:
$13.53
$15.26
52-Wochen-Spanne:
$3.11
$17.49
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Telefon
617-682-0917
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE
Compare AMLX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
13.99 | 1.58B | -665.00K | -144.74M | -123.48M | -1.5527 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-03 | Eingeleitet | Stifel | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf. - Yahoo Finance
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027 - TipRanks
[Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating - National Today
Winners Losers: How Amylyx Pharmaceuticals Inc. stock performs in weak economy2025 Market Sentiment & Real-Time Volume Surge Alerts - Naître et grandir
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Q1 EPS Forecast for Amylyx Pharmaceuticals Lifted by Analyst - MarketBeat
Amylyx (AMLX) Q4 2025 Earnings Call Transcript - AOL.com
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence - Investing.com India
H.C. Wainwright raises Amylyx stock price target to $34 on trial confidence By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Amylyx Leadership Triggers Buzz With Major Insider Stock Moves - TipRanks
Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear - Trefis
Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point (NASDAQ:AMLX) - Seeking Alpha
Tax-withholding sale by Amylyx Pharmaceuticals (AMLX) Chief Legal Officer - Stock Titan
Amylyx (AMLX) Co-CEO sells shares to cover RSU tax withholding - Stock Titan
Amylyx Pharmaceuticals (AMLX) CEO share sale covers tax obligations - Stock Titan
Amylyx (AMLX) CFO reports automatic tax-related sale of 7,909 shares - Stock Titan
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $34.00 - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2025 Earnings Call Transcript - Insider Monkey
The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following Narrower Losses And New Shelf Filings - simplywall.st
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Reduced Losses And Late Stage Pipeline Progress - Yahoo Finance
Amylyx Pharmaceuticals: 2026 Could Be Transformative Ahead of Avexitide Phase 3 Readout - Intellectia AI
Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout - MarketBeat
Page not foundAirwhon - MarketBeat
Amylyx Refocuses On Avexatide As LUCIDITY Milestone Raises Stakes - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Amylyx Pharmac - GuruFocus
Amylyx Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
AMLXForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
Amylyx Pharmaceuticals at TD Cowen: Strategic Insights on Avexitide and More - Investing.com Canada
Amylyx Pharmaceuticals Focuses on Advancing Avexitide for Post-Bariatric Hypoglycemia - National Today
Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Amylyx Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Amylyx Pharmaceuticals Q4 2025 shows EPS beat By Investing.com - Investing.com Canada
Earnings call transcript: Amylyx Pharmaceuticals Q4 2025 shows EPS beat - Investing.com
Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Quarterly Earnings Results - MarketBeat
Stifel Nicolaus Initiates Coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals Q4 operating income USD -36.605 million versus. Ibes estimate USD -40.4 million - marketscreener.com
Amylyx Pharmaceuticals (AMLX) files S-3ASR shelf to sell stock, debt, warrants - Stock Titan
Amylyx Pharmaceuticals Q4 Operating Income USD -36.605 Million Versus. Ibes Estimate USD -40.4 Million - TradingView
Amylyx Pharmaceuticals announced that its current cash reserves are expected to be sufficient to support the company's operations, not only covering the potential commercialization process of the new drug Avexitide, but also sustaining operations through 20 - Bitget
Stifel Initiates Amylyx Pharmaceuticals at Buy With $21 Price Target - marketscreener.com
Amylyx Pharmaceuticals Q4 Net Loss Narrows - marketscreener.com
AMYLYX PHARMACEUTICALS ($AMLX) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q4 Net Loss $0.30 a Share, vs. FactSet Est of $0.29 Loss - marketscreener.com
Amylyx shares fall over 3% on trial uncertainty despite earnings beat By Investing.com - Investing.com Australia
Amylyx shares fall over 3% on trial uncertainty despite earnings beat - Investing.com Nigeria
Amylyx Pharmaceuticals 10-K: $0M Revenue, $(0.29)–$(0.31) EPS range not stated - TradingView
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):